查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153447

2026-2034年全球癌症單株抗體市場規模、佔有率、趨勢和成長分析報告

Global Cancer Monoclonal Antibodies Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球抗癌單株抗體市場預計將從2025年的1,286.3億美元成長至2034年的6,076.8億美元，並預計在2026年至2034年間以18.83%的複合年成長率成長。受癌症發病率上升和對標靶治療需求不斷成長的推動，抗癌單株抗體市場正經歷顯著成長。單株抗體（mAb）是人工合成的蛋白質，旨在特異性靶向癌細胞，與傳統化療相比，可提供更精準的治療方案。隨著醫療專業人員和患者尋求更有效、毒性更小的治療方案，對抗癌單株抗體的需求預計將會增加，該市場預計將強勁擴張。目前的治療方法包括曲妥珠單抗和Rituximab等已上市的單株抗體，以及針對各種癌症類型的新藥。

此外，單株抗體技術的進步正在推動市場創新。雙特異性抗體、抗體藥物複合體（ADC）和免疫查核點抑制劑的開發，透過提高治療效果和特異性，正在革新癌症治療。這些創新不僅改善了治療結果，還透過最大限度地減少副作用，提高了患者的整體生活品質（QOL）。隨著對單株抗體新應用和聯合治療的研究不斷深入，在人們對更佳治療方案的期待推動下，市場預計將進一步擴張。

此外，對個人化醫療的日益重視正在塑造癌症單株抗體市場的趨勢。隨著醫療專業人員越來越認知到根據患者的基因和分子特徵量身定做治療方案的重要性，對符合個人化治療策略的單株抗體（mAb）的需求預計將會成長。這一趨勢在伴隨診斷領域尤其顯著，因為特定的生物標記可以指導選擇合適的單株抗體療法。隨著癌症單株抗體市場的不斷發展，創新療法、對個人化醫療的關注以及持續的研究將在推動未來成長方面發揮關鍵作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球癌症單株抗體市場：按類型分類

  • 市場分析、洞察與預測
  • 人性化
  • 人類
  • 嵌合體體
  • 小鼠來源

第5章 全球癌症單株抗體市場：依應用領域分類

  • 市場分析、洞察與預測
  • 血癌
  • 乳癌
  • 肺癌
  • 黑色素瘤
  • 結腸癌
  • 肝癌
  • 其他

第6章 全球癌症單株抗體市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 研究機構
  • 其他

第7章 全球癌症單株抗體市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Roche
    • Merck & Co
    • Bristol Myers Squibb
    • AstraZeneca
    • Johnson & Johnson
    • AbbVie
    • Amgen
    • Eli Lilly
    • Regeneron
    • Sanofi
    • Novartis
    • Pfizer
    • Gilead Sciences
    • BeiGene
    • Takeda
    • Daiichi Sankyo
    • Seagen
    • Genmab
    • UCB
    • Biogen
簡介目錄
Product Code: VMR11216177

The global cancer monoclonal antibodies market size is expected to reach USD 607.68 Billion in 2034 from USD 128.63 Billion in 2025, growing at a CAGR of 18.83% during 2026-2034.The cancer monoclonal antibodies market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Monoclonal antibodies (mAbs) are engineered proteins designed to specifically target cancer cells, offering a more precise treatment option compared to traditional chemotherapy. As healthcare providers and patients seek effective and less toxic treatment alternatives, the demand for cancer monoclonal antibodies is expected to rise, positioning this market for robust expansion. Current therapies include well-established mAbs such as trastuzumab and rituximab, as well as newer agents that target various cancer types.

Moreover, advancements in monoclonal antibody technology are propelling innovation within the market. The development of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors is revolutionizing cancer treatment by enhancing the efficacy and specificity of therapies. These innovations not only improve treatment outcomes but also minimize side effects, thereby improving the overall quality of life for patients. As research continues to explore new applications and combinations of monoclonal antibodies, the market is likely to expand further, driven by the promise of improved therapeutic options.

Additionally, the growing emphasis on personalized medicine is shaping the cancer monoclonal antibodies landscape. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patient profiles based on genetic and molecular characteristics, the demand for mAbs that align with personalized treatment strategies is likely to rise. This trend is particularly relevant in the context of companion diagnostics, where specific biomarkers guide the selection of appropriate monoclonal antibody therapies. As the cancer monoclonal antibodies market continues to evolve, the combination of innovative therapies, a focus on personalized care, and ongoing research will play a crucial role in driving its future growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Humanized
  • Human
  • Chimeric
  • Murine

By Application

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

By End-user

  • Hospitals
  • Research Institutes
  • Others

COMPANIES PROFILED

  • Roche, Merck & Co., Bristol Myers Squibb, AstraZeneca, Johnson & Johnson, AbbVie, Amgen, Eli Lilly, Regeneron, Sanofi, Novartis, Pfizer, Gilead Sciences, BeiGene, Takeda, Daiichi Sankyo, Seagen, Genmab, UCB, Biogen

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Murine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By End-user
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By End-user
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By End-user
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By End-user
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By End-user
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER MONOCLONAL ANTIBODIES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Roche
    • 9.2.2 Merck & Co
    • 9.2.3 Bristol Myers Squibb
    • 9.2.4 AstraZeneca
    • 9.2.5 Johnson & Johnson
    • 9.2.6 AbbVie
    • 9.2.7 Amgen
    • 9.2.8 Eli Lilly
    • 9.2.9 Regeneron
    • 9.2.10 Sanofi
    • 9.2.11 Novartis
    • 9.2.12 Pfizer
    • 9.2.13 Gilead Sciences
    • 9.2.14 BeiGene
    • 9.2.15 Takeda
    • 9.2.16 Daiichi Sankyo
    • 9.2.17 Seagen
    • 9.2.18 Genmab
    • 9.2.19 UCB
    • 9.2.20 Biogen